Teikoku Seiyaku Co., Ltd.

Medrx Co., Ltd

Asahi Kasei Kogyo Kabushiki Kaisha

Nippon Shinyaku Company, Ltd.

Teikoku Seiyaku Kabushiki Kaisha

Aicello Chemical Co., Ltd.

Aspion Co., Ltd.

Takeru Fujii

Hidetoshi Hamamoto

Akiya Yamada

Shigeyuki Takama

Toru Hibi

Hideakira Yokoyama

Seiichi Sako

Keiko Yamasaki

Tsutomu Suzuki

Kenichi Hashiudo

Takayuki Matsumoto

Seiichi Sakoh

Akihiko Hirata

Toshihiro Higashide

There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.

External preparation for wounds

The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R(SEQ ID No. 1) The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.

Peptide having an affinity for gp120

Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.

Intravaginal delivery of biologically active polypeptides

A large intestinal dissociative hard capsule comprising a capsule mainly composed of chitosan, the viscosity at 20.degree. C. of a solution obtained by dissolving the chitosan in an aqueous 1% by weight acetic acid solution being not higher than 100 cps and the degree of deacetilation of the chitosan being from 60 mol % to 98 mol %, having a coated layer of a polymer soluble in a liquid having pH of at least 5 on the surface of the capsule.

Large intestinal dissociative hard capsules

A high-absorbable transvaginal preparation having excellent absorbability of the active ingredient, which comprises a biologically active polypeptide and an absorption promoter comprising a polyoxyethylenealkylphenyl ether and one or more compounds selected from the group consisting of an N-acylamino acid, cholic acids, pectic acid, taurine, saccharin, glycyrrhizic acid, aspartame, or a salt thereof.

High-absorbable transvaginal preparation containing biologically active

Growing community of inventors

Naruto, Japan

Takeru Fujii